alexion report strong revenu earn volum growth compani
guidanc fell short consensu expect appear reflect manag
penchant conservat anyth els believ favor
data strong soliri launch gmg could make share top larg cap biotech
total revenu y/i vs consensu driven volum
growth y/i product sale driven growth y/i
asia pacif row sale impact on-going soft latin
america soliri sale y/i vs consensu grew doubl
digit y/i adjust pull
recruit headwind manag continu believ major pnh patient
yet initi treatment opportun ahu greater
pnh though compani break soliri sale indic alexion note
contribut gmg minim given octob approv patient verif
process take sever week
strensiq vs kanuma vs revenu also beat
expect strong volum growth y/i respect strensiq
fund agreement reach franc israel canada
earlier year alexion plan expand access addit countri
kanuma alexion continu target enrich patient popul lab test
plan add addit lab partnership addit kanuma fund agreement
reach itali spain israel netherland compani plan
expand addit countri year ahead kanuma revenu benefit
favor order adjust due part fund agreement
sinc alexion last updat earli januari addit gmg patient start
reimburs process enrol onesourc addit
patient initi treatment total gmg patient enrol
onesourc gmg patient soliri though launch remain earli stage
view number includ increment gain sinc januari impress
support gmg sale excess estim morn
gener neurologist progress also made payor alexion believ
approxim gmg patient commerci insur polici
coverag alexion target market includ estim refractori gmg patient
 germani japan regulatori file soliri gmg also
prioriti review canada view gmg market soliri
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand
trend soliri remain solid pnh ahu drug launch new market
gmg expect develop progress new soliri patent quell fear
competit alexion key complement franchis strensiq wit strong
launch appear destin blockbust statu asset plu minor
contribut kanuma allow compani post industry-lead financi
view alexion premier orphan diseas compani expect share appreci
investor gain convict soliri launch progress gmg
data phase trial
complet enrol pivot
trial ahu
data prevent soliri nmosd
soliri sale acceler approv
soliri rapid growth continu driven
soliri sale fall short expect
strong uptak gmg
commerci regulatori setback
strensiq kanuma lal-d
achiev
strensiq
soliri experi meaning
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ ahu
market could larger pnh market soliri also approv gener
myasthenia gavi gmg potenti new oppi beyond soliri strensiq kanuma
achiev commerci success respect peak sale
manag guidanc call y/i growth vs consensu
includ increment y/i clinic trial recruit headwind
other revenu guidanc consensu y/
sale growth project lower y/i growth despit fx
tailwind contribut gmg launch
manag provid detail call suggest conservat
factor guidanc estim assum high single-digit volum growth soliri
pnh ahu adjust clinic trial enrol vs low double-digit adjust
volum growth last quarter addit revenu expect
unfavor impact price headwind y/i vs headwind
headwind attribut soliri attribut metabol
franchis ascrib expans soliri countri lower price
annual lower strensiq per-pati price disclos previous reduc
revenu ep estim nearli compli guidanc new price
target reflect multipl non-gaap ep
phase trial pnh naiv patient soliri switch trial
read power non-inferior secondari statist analysi
superior alexion believ non-inferior coupl conveni dose
schedul vs inject per year would constitut success though
remain optimist measur superior either primari secondari metric
naiv studi co-primari endpoint ldh normal percentag patient
achiev transfus avoid though soliri effect ldh normal
publish alexion analyz data drug pivot trial design
studi data mind soliri switch studi primari endpoint
hemolysi measur percentag chang ldh follow data read-
out alexion plan submit regulatori file japan
approv pnh anticip addit trial treatment-na
ahu patient expect complet enrol data report
alexion initi singl pk-base registr phase studi deliv subq
weekli pnh ahu late enrol complet alexion prevent
studi soliri neuromyel optica spectrum disord nmosd compani
expect report data
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi
gmg soliri becom one success ultra-orphan drug
sale y/i given steadi new patient add stabl
price estim sale pnh
ahu gmg pivot trial soliri neuromyel optica nmo
complet enrol data expect mid next-gener soliri
candid seek advanc upon soliriss conveni possibl
efficaci profil enhanc franchis longev registr phase studi
use everi week dose paradigm complet enrol
pnh data enrol on-going ahu subq formul
employ dose also advanc develop phase trial
set begin late alexion busi becom diversifi
launch two addit ultra-orphan drug strensiq asfotas alfa
hypophosphatasia sever bone diseas approv europ
japan gener sale believ drug
potenti alexion acquir synageva bring late-
stage potenti blockbust product kanuma enzym replac therapi
lal defici unfortun alexion face challeng identifi lal-d
patient sale like far modest expect model
sale view alexion premier orphan diseas compani
expect share appreci investor gain convict
soliriss opportun gmg
cowen compani
reportedcowen estimatesoliri percent percent percent cowen
data soliriss pivot prevent trial nmo
execut gmg launch japan germani
launch addit ex-u territori uk franc israel canada
launch addit ex-u territori itali spain israel netherland
complet patient enrol phase trial ahu
releas top-lin phase data pnh nave switch studi
file approv pnh japan
complet patient enrol phase trial pediatr ahu
initi trial gmg igan
initi registr bridg trial subq formul
initi approv pnh
acquir in-licens addit earli stage candid
cowen compani
cowen compani
soliri sale y/i sale y/i sale y/i growthww strensiq sale y/i kanuma y/i gross total product oper oper oper incom non- tax net incom y/i base compens incom includ stock includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
soliri sale sale sale strensiq sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg lossshare-bas compens conting gain loss forward contractsdef asset liabilitiesaccount expens payable/accru use oper invest activitieschang market invest financ activitiesdebt issuanc excess tax benefit stock option mortagag note payableproce loan stock proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv singl product soliri risk
expect soliri includ potenti slowdown pnh market unknown
size ahu market regulatori clinic develop risk indic
includ nmo mg alexion share could also wit meaning downsid
meet failur
